CoreCap Advisors
ACAD icon

CoreCap Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

CoreCap Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-4
Closed -$101 – 3144
2026
Q2 		$101 Buy
+4
New +$88 ﹤0.01% 3074
2026
Q1 		– Sell
-15,366
Closed -$410K – 2937
2025
Q4 		$410K Sell
15,366
-2,956
-16% -$70.6K 0.01% 560
2025
Q3 		$391K Buy
+18,322
New +$433K 0.01% 585

Other funds holding ACAD

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Gradient Investments
Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Valeo Financial Advisors
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

CoreCap Advisors's ACAD Position: Q3 2026 in Review

CoreCap Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2026, closing a stake of 4 shares — an estimated $101 sold.

CoreCap Advisors first reported a position in ACAD in Q3 2025 and held it in 3 quarters. The position peaked at $410K in Q4 2025. 35 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • CoreCap Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • CoreCap Advisors sold 4 Acadia Pharmaceuticals shares in Q3 2026, an estimated $101.
  • CoreCap Advisors first reported a position in Acadia Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • CoreCap Advisors's Acadia Pharmaceuticals position peaked at $410K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.